Share on Facebook
EMA’s human medicines committee (CHMP) has adopted recommendations that will increase manufacturing capacity and supply of COVID-19 vaccines in the EU.
Additional manufacturing site and scaled-up process for Comirnaty
CHMP has approved an additional manufacturing site for the production of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer. The site, located in Saint Rémy sur Avre, France, is operated by Delpharm and will manufacture finished product. The site will allow to provide approximately up to 51 million additional doses in 2021.
EMA has also approved a new manufacturing line at BioNTech’s manufacturing site in Marburg, Germany which increases the active substance manufacturing capacity by approximately 410 million doses in 2021.
Created: 2022-01-14 12:42:21
Category: Public Health
Today the Commission has adopted the second EU4Health work programme. In 2022, the EU4Health will co...
Created: 2021-12-21 12:27:49
Category: Public Health
Non-communicable diseases
Presentations - Meeting of the Subgroup on Cancer (16 December 2021)
htt...